Impact of Breast Cancer Subtypes and Treatment on Survival: an Analysis Spanning Two Decades

Overview

Journal Cancer Epidemiol Biomarkers Prev

Specialties Biochemistry
Oncology
Public Health

Date 2012 Sep 20

PMID 22989461

Citations 114

Authors

Reina Haque

Syed A Ahmed

Galina Inzhakova

Jiaxiao Shi

Chantal Avila

Jonathan Polikoff

Leslie Bernstein

Shelley M Enger

Michael F Press

Affiliations

Soon will be listed here.

Abstract

Background: We investigated the impact of breast cancer molecular subtypes and treatment on survival in a cohort of medically insured women followed for more than 20 years.

Methods: We examined 934 female members of an integrated health care delivery system newly diagnosed with invasive breast cancer between 1988 and 1995 and followed them through 2008. Tumors were classified into four molecular subtypes on the basis of their expression profile: luminal A; luminal B; basal-like; and HER2-enriched. We followed women from the surgery date to death, health plan disenrollment, or study's end. HR and 95% confidence intervals (CI) were fit using Cox proportional hazards models adjusting for cancer treatments and tumor characteristics.

Results: A total of 223 (23.9%) women died because of breast cancer during the 21-year study period. Compared with women with luminal A tumors, women with HER2-enriched (HR 2.56, 95% CI 1.53-4.29) and luminal B tumors (HR 1.96, 95% CI: 1.08-3.54) had roughly a two-fold increased adjusted risk of breast cancer mortality. In addition, the survival curves suggest that risk of late mortality persists in women with luminal A tumors.

Conclusion: Among women with health care coverage, molecular subtypes were important predictors of breast cancer mortality. Women with HER2-enriched tumors and luminal B subtypes had the poorest survival despite adjusting for important covariates.

Impact: In a cohort followed for more than 20 years, women with HER2-enriched tumors had worse survival, but interestingly, the survival curve for women with luminal A tumors continued to steadily decline after 10 years of follow-up.

Citing Articles

Molecular Subtypes of Breast Cancer in Arab Women: Distribution and Prognostic Insights.

Elkum N, Aboussekhra A, Aboussekhra M, Aldalham H, Alshehri L, Alessy S J Epidemiol Glob Health. 2025; 15(1):36.

PMID: 40063309 PMC: 11893967. DOI: 10.1007/s44197-025-00376-z.

The prognostic and predictive value of the luminal-like subtype in hormone receptor-positive breast cancer: an analysis of the DATA trial.

Lammers S, Geurts S, Hermans K, Kooreman L, Swinkels A, Smorenburg C ESMO Open. 2025; 10(2):104154.

PMID: 39921934 PMC: 11850755. DOI: 10.1016/j.esmoop.2025.104154.

LINC00626 drives tamoxifen resistance in breast cancer cells by interaction with UPF1.

Yuan H, Zhou L, Hu W, Yang M Sci Rep. 2025; 15(1):2997.

PMID: 39848992 PMC: 11757752. DOI: 10.1038/s41598-025-86287-2.

Breast pericytes: a newly identified driver of tumor cell proliferation.

Del Toro K, Licon-Munoz Y, Crabtree W, Oper T, Robbins C, Hines W Front Oncol. 2025; 14():1455484.

PMID: 39741968 PMC: 11685225. DOI: 10.3389/fonc.2024.1455484.

Advancements in research and clinical management of interstitial lung injury associated with ADC drugs administration in breast cancer.

Zhu J, Jiang R, Zhang H, Fang Z, Zhou H, Wei Q Discov Oncol. 2024; 15(1):843.

PMID: 39729236 PMC: 11680531. DOI: 10.1007/s12672-024-01705-7.

References

Press M, Sauter G, Bernstein L, Villalobos I, Mirlacher M, Zhou J . Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res. 2005; 11(18):6598-607. DOI: 10.1158/1078-0432.CCR-05-0636. View

Sorlie T, Tibshirani R, Parker J, Hastie T, Marron J, Nobel A . Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100(14):8418-23. PMC: 166244. DOI: 10.1073/pnas.0932692100. View

Blows F, Driver K, Schmidt M, Broeks A, van Leeuwen F, Wesseling J . Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010; 7(5):e1000279. PMC: 2876119. DOI: 10.1371/journal.pmed.1000279. View

Enger S, Greif J, Polikoff J, Press M . Body weight correlates with mortality in early-stage breast cancer. Arch Surg. 2004; 139(9):954-58. DOI: 10.1001/archsurg.139.9.954. View

Chang H, Glaspy J, Allison M, Kass F, Elashoff R, Chung D . Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer. 2010; 116(18):4227-37. DOI: 10.1002/cncr.25309. View

Shavers V, Brown M . Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002; 94(5):334-57. DOI: 10.1093/jnci/94.5.334. View

Carey L, Perou C, Livasy C, Dressler L, Cowan D, Conway K . Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295(21):2492-502. DOI: 10.1001/jama.295.21.2492. View

Dawood S . Triple-negative breast cancer: epidemiology and management options. Drugs. 2010; 70(17):2247-58. DOI: 10.2165/11538150-000000000-00000. View

Sparano J, Wang M, Zhao F, Stearns V, Martino S, Ligibel J . Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. J Natl Cancer Inst. 2012; 104(5):406-14. PMC: 3295746. DOI: 10.1093/jnci/djr543. View

10.

Press M, Finn R, Cameron D, Di Leo A, Geyer C, Villalobos I . HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res. 2008; 14(23):7861-70. DOI: 10.1158/1078-0432.CCR-08-1056. View

11.

Haque R, Achacoso N, Fletcher S, Nekhlyudov L, Collins L, Schnitt S . Treatment of ductal carcinoma in situ among patients cared for in large integrated health plans. Am J Manag Care. 2010; 16(5):351-60. PMC: 3850784. View

12.

Millikan R, Newman B, Tse C, Moorman P, Conway K, Dressler L . Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2007; 109(1):123-39. PMC: 2443103. DOI: 10.1007/s10549-007-9632-6. View

13.

Carey L, Dees E, Sawyer L, Gatti L, Moore D, Collichio F . The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007; 13(8):2329-34. DOI: 10.1158/1078-0432.CCR-06-1109. View

14.

Yerushalmi R, Hayes M, Gelmon K, Chia S, Bajdik C, Norris B . A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with biomarkers. Clin Breast Cancer. 2009; 9(3):166-72. DOI: 10.3816/CBC.2009.n.027. View

15.

Gabos Z, Thoms J, Ghosh S, Hanson J, Deschenes J, Sabri S . The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer. Breast Cancer Res Treat. 2010; 124(1):187-94. DOI: 10.1007/s10549-010-1135-1. View

16.

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

17.

Ihemelandu C, Leffall Jr L, Dewitty R, Naab T, Mezghebe H, Makambi K . Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival. J Surg Res. 2007; 143(1):109-18. DOI: 10.1016/j.jss.2007.03.085. View

18.

Santana-Davila R, Perez E . Treatment options for patients with triple-negative breast cancer. J Hematol Oncol. 2010; 3:42. PMC: 2987865. DOI: 10.1186/1756-8722-3-42. View

19.

Schneider E, Zaslavsky A, Epstein A . Racial disparities in the quality of care for enrollees in medicare managed care. JAMA. 2002; 287(10):1288-94. DOI: 10.1001/jama.287.10.1288. View

20.

Perou C, Borresen-Dale A . Systems biology and genomics of breast cancer. Cold Spring Harb Perspect Biol. 2010; 3(2). PMC: 3039533. DOI: 10.1101/cshperspect.a003293. View